Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.69 |
| ▸ | TNF | P01375 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5941456 | 1.00 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL29840774 | 1.00 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL717039 | 1.00 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL7746552 | 0.93 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL14983194 | 0.93 | MEN1 (0.63) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL14983193 | 0.93 | MEN1 (0.63) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL18790608 | 0.93 | MEN1 (0.63) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL9924689 | 0.92 | TP53 (0.67) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL8267912 | 0.92 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4445016 | 0.91 | TNF (0.69) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | claimed |
| US-20130136770-A1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | CELGENE CORPORATION (US) | 2013-05-30 | — | — | US | claimed |
| EP-2555769-A2 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | Celgene Corporation (US) | 2013-02-13 | — | — | EP | claimed |
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | CELGENE CORPORATION (US) | 2012-06-28 | — | — | US | claimed |
| WO-2011127019-A2 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | CELGENE CORPORATION (US) | 2011-10-13 | — | — | WO | claimed |
| CN-1780616-B | Selective cytokine inhibitory drugs for treating disorders of the central nervous system | CELGENE CORP | 2010-05-12 | — | — | CN | claimed |
| CN-101309585-A | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury | CELGENE CORP (US) | 2008-11-19 | — | — | CN | claimed |
| US-20080267905-A1 | Methods and Compositions Using Selective Cytokine Inhibitory Drugs for Treatment and Management of Cancers and Other Diseases | CELGENE CORPORATION (US) | 2008-10-30 | — | — | US | claimed |
| EP-1755589-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION | CELGENE CORP (US) | 2007-11-07 | — | — | EP | claimed |
| US-20070207121-A1 | Methods of Using and Compositions Comprising Selective Cytokine Inhibitory Drugs for Treatment and Management of Macular Degeneration | CELGENE CORPORATION | 2007-09-06 | — | — | US | claimed |
| EP-1569599-A2 | METHODS OF USIG AND COMPOSITIONS COMPRISING (-)-3-(3,4-DIMETHOXY-PHENYL)-3-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONAMIDE | CELGENE CORPORATION (US) | 2005-09-07 | — | — | EP | claimed |
| US-20050142104-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders | CELGENE CORPORATION | 2005-06-30 | — | — | US | claimed |
| WO-2005044269-A1 | CYTOKINE INHIBITORY DRUGS FOR TREATMENT OF MACULAR DEGENERATION | CELGENE CORPORATION (US) | 2005-05-19 | — | — | WO | claimed |
| US-20040175382-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | CELGENE CORPORATION | 2004-09-09 | — | — | US | claimed |
| US-20040167199-A1 | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | CELGENE CORPORATION | 2004-08-26 | — | — | US | claimed |
| WO-2004054501-A2 | METHODS OF USIG AND COMPOSITIONS COMPRISING (-)-3-(3,4-DIMETHOXY-PHENYL)-3-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONAMIDE | CELGENE CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| WO-2004045597-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING (+)-3-(3,4-DIMETHOXY-PHENYL)-3-(1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PROPIONAMIDE | CELGENE CORPORATION (US) | 2004-06-03 | — | — | WO | claimed |
| US-20040091454-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | CELGENE CORPORATION | 2004-05-13 | — | — | US | claimed |
| US-20040087558-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | claimed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050142104-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders | PDE4A, PDE12, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4C 8/4885 |
| US-20130136770-A1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | PDE4A, PDE4B, IL4 | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
| US-20040091454-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | IL2, IL6, IL1B | PDE4A 295/4885PDE4B 348/4885PDE4C 352/4885 |
| US-20040167199-A1 | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide | PDE4A, PDE3A, PDE2A | PDE4A 1/4885PDE4B 4/4885PDE4C 5/4885 |
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | IL2, HDGF, VEGFA | PDE4A 1843/4885PDE4B 1724/4885PDE4C 1641/4885 |
| US-20080267905-A1 | Methods and Compositions Using Selective Cytokine Inhibitory Drugs for Treatment and Management of Cancers and Other Diseases | IL2, HDGF, TNF | PDE4A 821/4885PDE4B 617/4885PDE4C 611/4885 |
| US-20070207121-A1 | Methods of Using and Compositions Comprising Selective Cytokine Inhibitory Drugs for Treatment and Management of Macular Degeneration | IL2, IL6, IL1B | PDE4A 295/4885PDE4B 348/4885PDE4C 352/4885 |
| US-20040087558-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | IL6, IL2, IL6ST | PDE4A 498/4885PDE4B 561/4885PDE4C 612/4885 |
| US-20040175382-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | IL2, IL6, BDNF | PDE4A 1445/4885PDE4B 1668/4885PDE4C 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.